Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4LSPN)

• Drug Name: Ibudilast Drug Info
• Synonyms: Eyevinal; Ibudilastum; Ketas; Ibudilastum [Latin]; Ke Tas; AV 411; I 0157; KC 404; AV-411; Ibudilast [INN:JAN]; KC-404; Ketas (TN); MN-166; Ibudilast (JAN/INN); 1-(2-Isopropylpyrazolo(1,5-a)pyridin-3-yl)-2-methyl-1-propanone; 2-Isopropyl-3-isobutyrylpyrazolo(1,5-a)pyridine; 2-Methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl] 1-propanone; 2-methyl-1-(2-propan-2-ylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one; 3-Isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine; 3-Isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine

Indication

Disease Entry	ICD 11	Status	REF
Castleman's disease	4B2Y	Approved	[1]
Alcohol dependence	6C40.2	Phase 2	[2]
Amyotrophic lateral sclerosis	8B60.0	Phase 2	[3]
Methamphetamine dependence	6C46.2	Phase 2	[2]
Multiple sclerosis	8A40	Phase 2	[4]
Opioid dependence	6C43.2Z	Phase 2	[2]
Asthma	CA23	Investigative	[5]

• Cross-matching ID:
  PubChem CID: 3671
  ChEBI ID: CHEBI:31684
  CAS Number: CAS 50847-11-5
  TTD Drug ID: DM4LSPN

Molecule-Related Drug Atlas

Drug(s) Targeting Phosphodiesterase 3 (PDE3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cilostazol	DMZMSCT	Intermittent claudication	BD40.00	Approved	[6]
Oxtriphylline	DMLHSE3	Cough	MD12	Approved	[6]
Enoximone	DMQVZJD	Congestive heart failure	BD10	Approved	[7]
Olprinone	DMWBQKU	Heart failure	BD10-BD13	Approved	[8]
Inamrinone Lactate	DMRMFP4	Cardiac disease	BA00-BE2Z	Approved	[9]
Milrinone	DM8TUPF	Congestive heart failure	BD10	Approved	[6]
Tofisopam	DMTGNWU	Hyperuricaemia	5C55.Y	Phase 2	[10]
Tipelukast	DMS9BDQ	Asthma	CA23	Phase 2	[11]
RPL-554	DMLD4VQ	Allergic rhinitis	CA08.0	Phase 2	[12]
Org-30029	DMDZ4R2	Heart failure	BD10-BD13	Phase 2	[13]

Drug(s) Targeting Phosphodiesterase 4 (PDE4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apremilast	DMTWS9E	Psoriasis vulgaris	EA90	Approved	[14]
Oxtriphylline	DMLHSE3	Cough	MD12	Approved	[6]
Roflumilast	DMPGHY8	Asthma	CA23	Approved	[15]
crisaborole	DMNVKU6	Atopic dermatitis	EA80	Approved	[16]
Arofylline	DM84AD1	Chronic obstructive pulmonary disease	CA22	Phase 3	[17]
ARQ-151	DML61S4	Atopic dermatitis	EA80	Phase 3	[18]
SUN13834	DMPK34E	Gram-positive bacterial infection	1B74-1G40	Phase 2	[19]
ONO-6126	DMRT28X	Chronic obstructive pulmonary disease	CA22	Phase 2	[17]
E6005	DM1S489	Atopic dermatitis	EA80	Phase 2	[20]
IC-485	DMB1UYV	Chronic obstructive pulmonary disease	CA22	Phase 2	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase 3 (PDE3)	TTZCG4L	NOUNIPROTAC	Inhibitor	[1]
Phosphodiesterase 4 (PDE4)	TTV5CGO	NOUNIPROTAC	Inhibitor	[1]

References

• [1] Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Repurposing ibudilast to mitigate Alzheimer's disease by targeting inflammation. Brain. 2023 Mar 1;146(3):898-911.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [7] In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia-susceptible swine. Anesthesiology. 2003 Apr;98(4):944-9.
• [8] Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. Cardiovasc Drug Rev. 2002 Fall;20(3):163-74.
• [9] Effects of amrinone on hepatic ischemia-reperfusion injury in rats. J Hepatol. 2002 Jul;37(1):31-8.
• [10] The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
• [11] Company report (MediciNova)
• [12] Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.Lancet Respir Med.2013 Nov;1(9):714-27.
• [13] Effects of the positive inotropic agent Org 30029 on developed force and aequorin light transients in intact canine ventricular myocardium. Circ Res. 1993 Mar;72(3):597-606.
• [14] Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007 Mar;6(1):17-26.
• [15] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [16] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [17] Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
• [18] Trial of Roflumilast Cream for Chronic Plaque Psoriasis. N Engl J Med. 2020 Jul 16;383(3):229-239.
• [19] Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94.
• [20] Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther. 2013 Jul;346(1):105-12.